Robert Coury - Mylan

Robert Coury - Mylan
Total Compensation: $21.3 million

Details: Coury took a bit of a pay cut in his final year as Mylan's ($MYL) chief after steady raises from 2008 to 2010. His base salary jumped by about $800,000 to $1.78 million, and he saw increases in stock awards and incentive compensation, but his deferred compensation dropped by more than $3 million.

Coury will stay on as executive chairman of the genericsmaker, which plans to broaden its sales by launching its own prescription drugs in India, and Mylan is optimistic that the $17.5 million it paid for Pfizer's dry powder inhaler technology will help the company carve out a space in the world respiratory market.

Robert Coury - Mylan

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.